The Centre for Cellular and Molecular Biology (CCMB) in Hyderabad has signed a Memorandum of Understanding (MoU) with Aganitha to use generative AI solutions for creating new therapeutics and research tools for various diseases. This partnership aims to turn discoveries from CCMB’s research labs into potential treatments by utilizing Aganitha’s AI solutions for biopharma research and development.
Dr. Puran Singh Sijwali, a senior scientist at CCMB, mentioned that they are using Aganitha’s AI capabilities to identify and test antimalarial compounds for parasite drug targets. Dr. Raghunand Tirumalai, another senior scientist at CCMB, is working with Aganitha to discover small molecule inhibitors for proteins in Mycobacterium tuberculosis.
Dr. Janesh Kumar, a senior scientist at CCMB, is collaborating with Aganitha to develop nanobody binders that target GluD1 receptors in the central nervous system. These nanobodies could potentially lead to new treatments for neurological disorders like Alzheimer’s and epilepsy.
Prasad Chodavarapu, the co-founder and MD of Aganitha, emphasized the importance of partnerships between academia and industry to address human diseases. This collaboration between CCMB and Aganitha demonstrates the potential impact of combining research and technology to improve healthcare outcomes.
